Table 2.

Hemodynamic Parameters (Inhibitors Study).^a

		Baseline				Reperfusion
	n	HR, bpm	LVDP, cmH2O	RPP (LVDP × HR)	CF, mL/min	HR, bpm	LVDP, cmH2O	RPP (LVDP × HR)	CF, mL/min
Control (DMSO)	7	357 ± 12	112 ± 3	39 946 ± 1411	2.3 ± 0.1	317 ± 14	34 ± 7	10 617 ± 1955	1.3 ± 0.1
PFT-α	5	334 ± 13	117 ± 4	38 933 ± 2093	2.6 ± 0.3	299 ± 24	43 ± 8	12 753 ± 2409	1.4 ± 0.3
PFT-α R	5	347 ± 17	117 ± 5	40 482 ± 1676	2.5 ± 0.3	309 ± 27	42 ± 10	13 268 ± 3363	1.5 ±0.5
PFT-μ 25 μmol/L/15 minutes	6	357 ± 9	113 ± 4	40 413 ± 1318	2.3 ± 0.2	282 ± 12	33 ± 14	9782 ± 4185	1.4 ± 0.2
PFT- μ 25 μmol/L/5 minutes	5	343 ± 8	109 ± 3	37 362 ± 1177	2.6 ± 0.3	311 ± 11	49 ± 6	15 311 ± 1997	1.4 ± 0.2
PFT- μ 10 μmol/L/5 minutes	5	373 ± 9	108 ± 3	40 409 ± 1681	2.1 ± 0.2	299 ± 16	44 ± 10	12 666 ± 2263	1.1 ± 0.2
PFT- μ 1 μmol/L/5 minutes	5	367 ± 12	117 ± 4	42 734 ± 1051	2.1 ± 0.2	275 ± 14	56 ± 15	14 783 ± 3454	1.1 ± 0.2
PFT- μ 25 μmol/L R	5	346 ± 8	120 ± 5	41 558 ± 1964	2.6 ± 0.3	322 ± 12	45 ± 7	14 422 ± 1980	1.3 ± 0.2

Abbreviations: HR, heart rate; LVDP, left ventricular developed pressure; RPP, rate pressure product; CF, coronary flow; PFT, pifithrin.

^aData are mean + SEM. End of perfusion = 15 minutes after perfusion with each drug.